Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
332 stopped studies mapped to Pancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 332 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The… | Phase 1 | withdrawn | Aug 22, 2022 | M.D. Anderson Cancer Center | Per PI's request | Other (stated, no rule matched) |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | terminated | May 30, 2014 | QED Therapeutics, a BridgeBio company | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints).… | Safety / toxicity |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Phase 2 | withdrawn | Jan 31, 2022 | HonorHealth Research Institute | enrollment challenges | Enrollment / accrual |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | N/A | withdrawn | Aug 4, 2015 | University of Florida | Original PI left the institution. No subjects enrolled | Investigator |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | — | terminated | Mar 10, 2006 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking… | Phase 1 | terminated | Apr 18, 2017 | BioNTech Research & Development, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | Phase 1 | withdrawn | Apr 21, 2021 | University of Oxford | Lack of recruitment | Enrollment / accrual |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma…(AntiCEA_CART) | Phase 1 | terminated | Jan 28, 2019 | Sorrento Therapeutics, Inc. | Limited enrollment. | Enrollment / accrual |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic…(ARTEMIS) | — | terminated | May 19, 2022 | Invitae Corporation | Low site engagement and accrual | Enrollment / accrual |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | Phase 2 | terminated | Sep 3, 2019 | Sunnybrook Health Sciences Centre | Lack of Funding | Funding |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | Phase 1 | terminated | Mar 11, 2020 | Danielle Kim Turgeon | Terminated due to lack of dimer. | Other (stated, no rule matched) |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | — | terminated | May 26, 2020 | OHSU Knight Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Phase 2 | terminated | Oct 30, 2018 | Northwestern University | The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim… | Efficacy / futility |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar…(ENBD) | N/A | withdrawn | Nov 27, 2017 | Changhai Hospital | Failure to recruit patients | Enrollment / accrual |
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent… | Phase 1 | withdrawn | Nov 17, 2020 | Ipsen | Business decision not related to any safety or tolerability concern | Safety / toxicity |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic… | Phase 1 | terminated | Feb 2, 2012 | Washington University School of Medicine | Equipment that was used in the study was discontinued | Other (stated, no rule matched) |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | — | withdrawn | Mar 13, 2020 | Beth Israel Deaconess Medical Center | Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected to… | COVID-19 / pandemic |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating…(HOPE) | N/A | withdrawn | Jan 22, 2021 | Poitiers University Hospital | No enrollment | Enrollment / accrual |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | N/A | terminated | Jan 6, 2017 | University of Washington | Termination due to slow accrual | Enrollment / accrual |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase 2 | withdrawn | May 20, 2021 | Walid Shaib, MD | Funder decision | Other (stated, no rule matched) |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving… | Early Phase 1 | withdrawn | Jun 10, 2011 | University Hospitals Cleveland Medical Center | Study never started | Other (stated, no rule matched) |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy… | Phase 2 | withdrawn | Sep 14, 2020 | Samsung Medical Center | problem of sponsor | Other (stated, no rule matched) |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | Phase 2 | terminated | Jan 27, 2021 | AIO-Studien-gGmbH | Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine… | Enrollment / accrual |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | Phase 2 | withdrawn | Aug 1, 2016 | Wake Forest University Health Sciences | no accrual rate | Enrollment / accrual |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | Phase 1 | withdrawn | Jul 21, 2020 | Jordan Kharofa | Difficulty accruing | Enrollment / accrual |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment… | Phase 2 | withdrawn | Aug 25, 2021 | Fudan University | Repeat registration | Other (stated, no rule matched) |
| NCT03784417 | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma | N/A | terminated | Dec 21, 2018 | Catholic University of the Sacred Heart | device unavalaible | Other (stated, no rule matched) |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Phase 2 | terminated | Dec 1, 2020 | American University of Beirut Medical Center | pharma company decision to withdraw the financial and IMP support | Funding |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab… | Phase 2 | terminated | Dec 5, 2016 | Aiwu Ruth He, MD | Manufacturer discontinued Sylatron | Drug supply |
| NCT03472833 | High-dose Vitamin D3 in Pancreas Cancer(VITdCUT) | Phase 3 | terminated | Mar 21, 2018 | Medical University of Graz | slow recruitment, patients lost to follow-up due to Covid-19 pandemic. | COVID-19 / pandemic |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jan 6, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer…(PANTHEON) | Phase 2 | terminated | Nov 6, 2017 | AIO-Studien-gGmbH | slow recruitment | Enrollment / accrual |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | Phase 1 | terminated | Feb 22, 2016 | BioNTech Research & Development, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients… | Phase 1 | withdrawn | Jan 16, 2012 | Gilead Sciences | no subjects enrolled | Enrollment / accrual |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | N/A | withdrawn | Aug 13, 2020 | Michael Lidsky, M.D. | No subjects enrolled due to availability of device commercially. | Enrollment / accrual |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic… | Phase 2 | withdrawn | Jul 21, 2020 | Jiangsu HengRui Medicine Co., Ltd. | It is difficult to screening subject | Other (stated, no rule matched) |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 2, 2018 | National Cancer Institute (NCI) | Study was closed after one treatment related death. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 15, 2023source: clinicaltrials